

U.S. Serial No.: 10/024,858
Group Art Unit: 1615

Amendments to the claims:

25. (Previously Presented) A composition, that reduces the incidence of nausea and vomiting associated with the administration of paroxetine, comprising paroxetine, or a pharmaceutically acceptable salt thereof, in a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases the paroxetine predominantly in the small intestine.

26. (Currently Amended) A method of treating one or more disease states selected from: Alcoholism, Anxiety, Depression, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymia and Substance Abuse, which comprises administering an effective amount of a controlled and delayed release swallow pharmaceutical formulation of claim 25 that, upon administration, releases paroxetine or a pharmaceutically acceptable salt thereof, predominantly in the small intestine to an individual in need thereof.